GHSI - Guardion Health Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.5265
-0.0057 (-1.07%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.5322
Open0.5005
Bid0.5230 x 800
Ask0.5300 x 800
Day's Range0.4710 - 0.5400
52 Week Range0.2020 - 4.0000
Volume3,351,570
Avg. Volume7,585,540
Market Cap18.814M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3850
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Best & worst performing IPOs in 2019
    Yahoo Finance Video

    Best & worst performing IPOs in 2019

    Barron's is breaking down the best and worst IPOs of 2019, with Beyond Meat, Turning Point Therapeutics, CrowdStrike Holdings, and Zoom Video Communications sitting at the top. Yahoo Finance's Zack Guzman, Heidi Chung and Katie Prentke English, Harness Wealth Co-Founder, discuss.

  • GlobeNewswire

    Guardion® Announces Statistically Significant Blood Assay Study Results

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI) announced the formal results of a blood assay study that established that Lumega-Z, Guardion’s proprietary medical food designed specifically to replenish and restore the eye’s macular protective pigment, provided 40 times higher concentrations and bioavailability of mesozeaxanthin in the blood as compared to over-the-counter AREDS2 gel cap supplements. The study was conducted by Professor Richard A. Bone, BSc, PhD, a member of the faculty of the Department of Physics at Florida International University in Miami, Florida. Dr. Bone is also a member of the Company’s Scientific Advisory Board.

  • GlobeNewswire

    Guardion Health Sciences Acquires the NutriGuard Brand of Products

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), through its newly-formed wholly-owned subsidiary, NutriGuard Formulations, Inc., has acquired certain assets of NutriGuard Research, Inc. (“NutriGuard”). This acquisition, which was effective as of September 20, 2019, provides a direct-to-consumer (“DTC”) capability for the Company. Guardion is a leader in the field of ocular health technologies and products.

  • GlobeNewswire

    Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI) announced that it has completed development of its proprietary CSV-2000 standardized contrast sensitivity test and will introduce the commercial product at Vision Expo West, a conference for ophthalmic professionals, in Las Vegas, Nevada, from September 18 to 21, 2019. The CSV-2000 is the only computer-generated vision testing instrument available that will provide the optical marketplace with the Company’s proprietary, industry-standard contrast sensitivity test, along with a full suite of standard vision testing protocols. The proprietary standardization methodology incorporated into the CSV-2000 includes a patented technology known as AcQviz that automatically and constantly measures and adjusts screen luminance to a fixed standard light level for vision testing.

  • GlobeNewswire

    Guardion Health Sciences Closes $5.8 Million Underwritten Public Offering

    San Diego, CA , Aug. 15, 2019 -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), today announced the closing of its previously announced.

  • GlobeNewswire

    Guardion Health Sciences Announces an Increase in the Pricing of its Previously Announced Underwritten Public Offering

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), previously announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to 13,000,000 shares of the Company’s common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $0.45 per share and warrant, which is an increase of $0.05 per share and warrant than previously disclosed. The shares of common stock or pre-funded warrants and the accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.

  • GlobeNewswire

    Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to 13,000,000 shares of the Company’s common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $0.40 per share and warrant. The shares of common stock or pre-funded warrants and the accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.

  • GlobeNewswire

    Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), today announced its unaudited interim financial results for the three months and six months ended June 30, 2019. The increase was primarily due to growth in the Company’s Lumega-Z customer base and in its VectorVision vision testing diagnostic products. The increase was due to primarily to engineering development costs associated with the development of the Company’s CSV-2000 VectorVision product.

  • GlobeNewswire

    Foundation Fighting Blindness selects Guardion’s VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-Center Clinical Trial

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), announced that its standardized vision testing instrument, the CSV-1000, has been selected by the Foundation Fighting Blindness for inclusion in a large-scale multi-center long-term clinical trial, the PRO-EYS Study. This study is being conducted to evaluate vision loss and progression in patients with degenerative retinal disease. The CSV-1000 is manufactured by Guardion’s VectorVision subsidiary.

  • What Type Of Shareholder Owns Guardion Health Sciences, Inc.'s (NASDAQ:GHSI)?
    Simply Wall St.

    What Type Of Shareholder Owns Guardion Health Sciences, Inc.'s (NASDAQ:GHSI)?

    Every investor in Guardion Health Sciences, Inc. (NASDAQ:GHSI) should be aware of the most powerful shareholder...

  • GlobeNewswire

    Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), announced that it has received a patent from the Patents Registry in Hong Kong (Hong Kong Patent No. HK1204758 titled “Apparatus for Use in the Measurement of Macular Pigment Optical Density and/or Lens Optical Density of an Eye”) for its proprietary medical device, the MapcatSF®. The MapcatSF® measures the macular pigment density in the human eye, thus facilitating treatment for several ocular conditions and diseases that affect a large number of patients. Dr David Evans, Guardion’s Chief Science Officer, commenting on the granting of this patent by Hong Kong, stated, “The granting of this patent in Honk Kong represents an important step in Guardion’s process to expand into the large Asian markets, where evidenced-based eye care is of great interest to both physicians and consumers.

  • GlobeNewswire

    Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, announced that it has received a patent from the European Union (European Patent No. 2,811,892 titled “Apparatus for Use in the Measurement of Macular Pigment Optical Density and/or Lens Optical Density of an Eye”) for its proprietary medical device, the MapcatSF®. The MapcatSF® measures the macular pigment density in the human eye, thus facilitating treatment for several ocular conditions and diseases that affect a large number of patients.

  • GlobeNewswire

    Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’

    In an IRB-approved trial conducted at the New York Eye and Ear Infirmary, the parent compound of GlaucoCetin, GlaucoHealth, designed by Robert Ritch, MD, successfully reversed mitochondrial dysfunction in patients with glaucoma. San Diego, CA, June 04, 2019 (GLOBE NEWSWIRE) --  Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the launch of the Company’s second ocular health formula.

  • GlobeNewswire

    Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2

    The AREDS 2 Group showed no statistical change. San Diego, CA, May 09, 2019 (GLOBE NEWSWIRE) --  Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the results of a study from research scientists at the Western University College of Optometry to clinically evaluate the visual benefits of the Company’s micronized liquid formula Lumega-Z as compared to the AREDS 2 softgel supplement in individuals with retinal drusen and at risk of developing Age-Related Macular Degeneration (AMD).

  • GlobeNewswire

    Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the results of a study from research scientists at the University of Texas, San Antonio (USTA), Texas, on the effects of the Company’s Lumega-Z medical food on pericentral FDT (i.e.

  • GlobeNewswire

    Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced that it was recently notified by the State Intellectual Property Office of the People’s Republic of China (“China”) that it has been granted trademark registrations in China for its proprietary medical food, Lumega-Z (Registration No. 27151643), and for its proprietary medical device, the MapcatSF (Registration No. 27151644). The trademark registration for Lumega-Z is effective from November 7, 2018 to November 6, 2028, and the trademark registration for the MapcatSF is effective from October 28, 2018 to October 27, 2028.

  • GlobeNewswire

    Results of Lumega-Z Data to be Presented at ARVO

    Guardion Health Sciences, Inc.’s (the “Company”) Scientific Advisory Board member, Dr. William Sponsel will be presenting an abstract at the Association for Research in Vision and Ophthalmology (“ARVO”) 2019 Annual Meeting in Vancouver, Canada, which will be held from April 28, 2019 to May 2, 2019. The study assessed the potential utility of the Company’s medical food product, Lumega-Z, which is designed to restore the macular protective pigment layer. The abstract concludes that in patients who had ordered 12 consecutive month’s supply of Lumega-Z, Lumega-Z treatment was associated with significant improvement in visual field function among patients with severe glaucoma who had previously shown degeneration despite having had excellent intraocular pressure control.

  • WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services
    PR Newswire

    WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services

    JERSEY CITY, N.J. , April 11, 2019 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the closing of the initial public offering ...

  • GlobeNewswire

    Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering

    Guardion Health Sciences Inc. (“Guardion”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced that it closed its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for total gross proceeds of $5.0 million, before deducting underwriting discounts and commissions and other offering costs and expenses payable by Guardion. In addition, Guardion has granted the underwriters a 45-day option to purchase up to 187,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

  • Business Wire

    Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering

    Guardion Health Sciences Inc. (“Guardion”) (Nasdaq:GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for total gross proceeds of $5.0 million, before deducting underwriting discounts and commissions and other offering costs and expenses payable by Guardion. In addition, Guardion has granted the underwriters a 45-day option to purchase up to 187,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.